Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Syndax Pharmaceuticals, Inc.

https://www.syndax.com/

Latest From Syndax Pharmaceuticals, Inc.

Finance Watch: Public Biopharma Firms Take Advantage Of Relative Upswing

Public Company Edition: Prometheus brought in $500m from a follow-on offering after reporting positive mid-stage results for its TL1A inhibitor. Even Novavax, struggling to make money from its COVID-19 vaccine, raised cash in dual offerings, but its valuation dropped significantly afterward.

Financing Business Strategies

Spain's Oryzon Bucks Trend To Seek NASDAQ Listing

The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.


Financing Business Strategies

‘The Next Tulip Mania?’ – Fidelity, Gurnet, Biogen Put A Lens To Funding, Valuations

Venture capital funding for biotechs remains aplenty even as listed companies’ stock prices drop. Biogen’s Papadopoulos, Fidelity’s Kaul and Gurnet’s and ex-Sanofi Viehbacher deliberate on whether there is a valuation disconnect and if this is the next "tulip mania."

Commercial Business Strategies

IPO Update: Mid-Year Average Return Deceptively Positive In Down Market

The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities. 

Financing Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register